FINKELSTEIN J J 4
4 · REGENERX BIOPHARMACEUTICALS INC · Filed Oct 20, 2017
Insider Transaction Report
Form 4
FINKELSTEIN J J
DirectorPresident and CEO
Transactions
- Exercise of In-Money
Common Stock
2017-10-19$0.15/sh+20,000$3,000→ 1,533,535 total - Conversion
Common Stock
2017-10-19$0.15/sh+125,347$18,802→ 1,513,535 total - Conversion
Convertible Promissory Note (right to buy)
2017-10-19−125,347→ 0 totalExercise: $0.15From: 2012-10-19Exp: 2017-10-19→ Common Stock (125,347 underlying) - Exercise of In-Money
Common Stock Warrant (right to buy)
2017-10-19−20,000→ 0 totalExercise: $0.15From: 2013-04-19Exp: 2017-10-19→ Common Stock (20,000 underlying)
Footnotes (1)
- [F1]The Convertible Promissory Note in the principal amount of $15,000 accrued $3,802.05 in interest and both principal and interest were converted into 125,347 shares of common stock at a conversion price of $0.15 per share.